Hodgkin's Pro Bowler Picks up ESPY Award Last Night
Carolina US Football linebacker Mark Fields picked up an ESPY Award for best comeback Wednesday night before he begins treatment for a recurrence of Hodgkin's lymphoma.
"This will be some inspiration," Fields said, holding his trophy.
He will start a round of chemotherapy Thursday at the Mayo Clinic in Phoenix, Arizona and will miss the upcoming NFL season. "My intentions are to come back again. If you're going to get cancer, this is kind of the one to get. It's quite devastating, but all you can do is keep pounding," he said.
Sidelined because of cancer for the first time in 2003 when the Panthers made the Super Bowl, Fields returned last season and made the Pro Bowl for the second time. He had 60 tackles, four sacks, one forced fumble, one fumble recovery and one interception.
2005 ESPY Info - Best Comeback
More Articles
More Articles
Amazon.com is pleased to have the Lymphoma Information Network in the family of Amazon.com associates. We've agreed to ship items...
The question ought to be what are myelodysplastic syndromes (MDS), since this is a group of similar blood and bone marrow diseases that...
Merkel Cell Carcinoma (MCC) is a very rare and aggressive skin cancer that usually develops when a person is in his or her 70s. It is...
At some point, the Seattle biotech company Cell Therapeutics Inc (CTI) should earn an entry in the Guinness Book of World Records for utter and...
Site Beginnings
This site was started as Lymphoma Resource Page(s) in 1994. The site was designed to collect lymphoma...
Three papers appearing in the journal Blood and pointing towards a regulator-suppressor pill could offer hope to blood cancer...
The US Food and Drug Administration (FDA) has granted a third so-called Breakthrough Therapy Designation for the investigational oral...
The US Food and Drug Administration today has approved an expanded use of Imbruvica (ibrutinib) in patients with...
The U.S. Food and Drug Administration has announced that it has granted "Breakthrough Therapy Designation" for the investigational agent...
According to a new study published in the Proceedings of the National Academy of Sciences, a team from the University of California, San...
Pharmacyclics has announced that the company has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for...
New research suggests that frontline radioimmunotherapy...
Gilead Sciences has announced results of the company's Phase II study of its investigational compound idelalisib, an oral inhibitor of...
